Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q4 FY23 results · Jan–Mar 2023
Bliss GVS Pharma reported revenue from operations of ₹184.78 crore (up 10.6% from Q4 FY22) and net profit of ₹3.46 crore (down 85.2% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 184.78 | 167.06 | +10.6% | 205.72 | −10.2% |
| Other income | 2.98 | 12.19 | −75.6% | 5.65 | −47.3% |
| Total income | 187.76 | 179.25 | +4.7% | 211.36 | −11.2% |
| Profit before tax | (0.75) | 26.45 | Turned loss | 47.43 | Turned loss |
| Net profit for the period | 3.46 | 23.47 | −85.2% | 29.79 | −88.4% |
| Attributable to shareholders of the company | 3.34 | 19.63 | −83.0% | 27.94 | −88.0% |
| EPS, basic (₹) | 0.34 | 1.90 | −82.1% | 2.68 | −87.3% |
| Net margin (%) | 1.9 | 14.0 | 14.5 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 143.42 | 138.30 | +3.7% | 168.79 | −15.0% |
| Other income | 6.48 | 12.44 | −47.9% | 11.42 | −43.3% |
| Total income | 149.90 | 150.74 | −0.6% | 180.21 | −16.8% |
| Profit before tax | 8.44 | 16.54 | −48.9% | 39.89 | −78.8% |
| Net profit for the period | 6.11 | 9.47 | −35.5% | 29.28 | −79.1% |
| EPS, basic (₹) | 0.60 | 1.85 | −67.6% | 2.81 | −78.6% |
| Net margin (%) | 4.3 | 6.8 | 17.3 |
Consolidated
- Filed with BSE
- 18 May 2023, 12:34 IST
- Board meeting
- 11 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 May 2023, 12:34 IST
- Board meeting
- 11 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE